Laura Barrell outlines how the UK is emerging from the trials of Brexit and coronavirus (COVID-19) to take a leading international role in the future of pharma and healthcare.
Following Brexit, the UK is looking for new international trade opportunities. In life sciences as well as other sectors, where better to push on than with India? That seems to be the UK Government's view.
Well, it finally happened. After months of complex negotiations and stand-offs that took Europe to the brink and back, the EU and UK finally agreed a trade and co-operation deal on Christmas Eve.
In July 2020, the European Court of Justice dealt a major blow to organisations that transfer personal data to the US and other jurisdictions, primarily with the striking down of the EU-US Privacy Shield.
Many industries have been hit by coronavirus (COVID-19). To some people's surprise, this has also been in pharma, as can be seen from the latest results from GlaxoSmithKline (GSK) and AstraZeneca (AZ).
The UK is leading the way when it comes to advanced therapies, as we heard recently at the 2020 PING Conference - Britain's Great Life Sciences Future: Genomics Personalised Medicine and AI.
The European Court of Justice (ECJ) has given a judgment on the extent to which the application of national laws regulating medicines can limit the activities of online pharmacies.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a guidance note on new assessment routes for pharmaceutical products from the end of the Brexit transition period.
The UK marked its place as the frontrunner in the field of genomics many years ago when it created genomics focused institutions such as the UK BioBank and Genomics England...
Stevenage has been classified by the Department for International Trade (DIT) as a High Potential Opportunity (HPO) zone in recognition of its leading cell and gene therapy cluster.
